Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05192122 | Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD(HEME-20) | recruiting | Phase 1 | 50 | University of Illinois at ChicagoOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07284927 | Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies | recruiting | Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 16, 2025 |
| clinicaltrials |
| NCT07052695 | Mosunetuzumab for CLL MRD Clearance | recruiting | Phase 1 / Phase 2 | 40 | Inhye AhnOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07153068 | SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies | recruiting | Phase 1 / Phase 2 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07280494 | To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT(S101MRD) | recruiting | Phase 1 | 18 | Peking University People's HospitalOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT06518551 | Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM | recruiting | Phase 1 / Phase 2 | 49 | Omar Nadeem, MDOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07179679 | A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors | recruiting | Phase 1 | 42 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 11, 2025 | clinicaltrials |
| NCT05602363 | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | recruiting | Phase 1 | 120 | Carna Biosciences, Inc.INDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
| NCT04925609 | Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors(Briga-PED) | recruiting | Phase 1 / Phase 2 | 65 | Princess Maxima Center for Pediatric OncologyOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT06421948 | Linperlisib Combined With Chidamide in Patients With PTCL | recruiting | Phase 1 / Phase 2 | 134 | Yanyan LiuOTHER_GOV | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06645678 | Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma(MELT-MM) | recruiting | Phase 1 / Phase 2 | 75 | YOUNGIL KOHOTHER | 2 | Dec 3, 2025 | clinicaltrials |
| NCT06080191 | Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL | recruiting | Phase 1 | 24 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06559189 | CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL | recruiting | Phase 1 | 53 | University of Colorado, DenverOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT06316427 | Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies | recruiting | Phase 1 / Phase 2 | 80 | Beijing GoBroad HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07003555 | Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration | recruiting | Phase 1 | 18 | Beijing GoBroad HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07003568 | Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration | recruiting | Phase 1 | 18 | Beijing GoBroad HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07070323 | A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies(nanobody CD5) | recruiting | Phase 1 / Phase 2 | 54 | Beijing GoBroad HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT05741359 | The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma | recruiting | Phase 1 | 18 | Bioray LaboratoriesINDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07139509 | Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma(UCAR-T_MM-XA) | recruiting | Phase 1 | 18 | Xi'an No.3 HospitalOTHER_GOV | 1 | Nov 25, 2025 | clinicaltrials |
| NCT06507514 | Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL | recruiting | Phase 1 | 4 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT04795882 | A New Study Evaluating the Activity of Modular CAR T for mYeloma(MCARTY) | recruiting | Phase 1 | 27 | University College, LondonOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06707259 | Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL | recruiting | Phase 1 | 24 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT07239323 | In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies | recruiting | Phase 1 | 24 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT04999384 | First in Human, Dose Escalation Study of AN4005 | recruiting | Phase 1 | 31 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 2 | Nov 18, 2025 | clinicaltrials |
| NCT07053670 | A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )(CT1190B) | recruiting | Phase 1 | 27 | Tongji HospitalOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05643742 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies | recruiting | Phase 1 / Phase 2 | 120 | CRISPR Therapeutics AGINDUSTRY | 2 | Nov 14, 2025 | clinicaltrials |
| NCT06420089 | CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)(VIPER101) | recruiting | Phase 1 | 30 | Vittoria BiotherapeuticsINDUSTRY | 1 | Nov 10, 2025 | clinicaltrials |
| NCT06916767 | Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma | recruiting | Phase 1 | 18 | Paolo Caimi, MDOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05943496 | Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | recruiting | Phase 1 | 27 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT04260022 | Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL | recruiting | Phase 1 | 242 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Nov 5, 2025 | clinicaltrials |
| NCT03595917 | ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML | recruiting | Phase 1 | 40 | Marlise Luskin, MDOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT05363111 | Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT02508038 | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | recruiting | Phase 1 | 22 | University of Wisconsin, MadisonOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT06712810 | Q702 for the Treatment of Patients With Hematologic Malignancies | recruiting | Phase 1 | 46 | Mayo ClinicOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT05705570 | Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies(CARTHIAE-1) | recruiting | Phase 1 | 30 | Nelson HamerschlakOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05722418 | CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma(CaMMouflage) | recruiting | Phase 1 | 50 | Caribou Biosciences, Inc.INDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05794958 | Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel | recruiting | Phase 1 | 20 | Stanford UniversityOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT04234048 | Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 46 | SciTech Development, Inc.INDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT06037018 | Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies | recruiting | Phase 1 | 44 | CytoCares IncINDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT06709469 | Phase I Clinical Trial of CART Cell Therapy for Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults(REALL_CART) | recruiting | Phase 1 | 10 | Instituto de Investigación Hospital Universitario La PazOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT04162353 | BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma | recruiting | Phase 1 | 12 | iCell Gene TherapeuticsINDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05658640 | HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies(HEM-iSMART D) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 15 | Sep 16, 2025 | clinicaltrials |
| NCT05698147 | Selinexor in Combination With MTX+Ritu to Treat R/R CNSL | recruiting | Phase 1 / Phase 2 | 30 | Tong Chen, MDOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05745714 | HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART C) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 14 | Sep 16, 2025 | clinicaltrials |
| NCT05751044 | HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART B) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 14 | Sep 16, 2025 | clinicaltrials |
| NCT05357651 | A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001） | recruiting | Phase 1 | 100 | L & L Bio Co., Ltd., Ningbo, ChinaINDUSTRY | 1 | Sep 11, 2025 | clinicaltrials |
| NCT04150497 | Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) | recruiting | Phase 1 / Phase 2 | 52 | Cellectis S.A.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | recruiting | Phase 1 | 345 | Nurix Therapeutics, Inc.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT05372354 | A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 260 | Bristol-Myers SquibbINDUSTRY | 5 | Sep 5, 2025 | clinicaltrials |
| NCT07109518 | uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies | recruiting | Phase 1 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 3, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 18, 2025source: clinicaltrials